Beauty Health Appoints New CEO

TL;DR

Beauty Health names Andrew Staniforth permanent CEO, effective immediately.

AI Summary

On December 12, 2024, The Beauty Health Company announced the appointment of Andrew D. Staniforth as Chief Executive Officer, effective immediately. Staniforth, who previously served as interim CEO, will also join the Board of Directors. He has been with the company since 2021, holding various leadership roles.

Why It Matters

The appointment of a permanent CEO is a significant leadership change that could impact the company's strategic direction and operational execution.

Risk Assessment

Risk Level: medium — CEO changes can introduce uncertainty regarding future strategy and operational stability.

Key Players & Entities

• Andrew D. Staniforth (person) — Appointed Chief Executive Officer and Board Member
• The Beauty Health Company (company) — Registrant
• December 12, 2024 (date) — Effective date of appointment
• 2021 (date) — Year Staniforth joined the company

FAQ

Key Financial Figures

• $0.0001 — tered Class A Common Stock, par value $0.0001 per share SKIN The Nasdaq Capital Marke

Filing Documents

• skin-20241212.htm (8-K) — 38KB
• exhibit991-beautyhealthsfb.htm (EX-99.1) — 7KB
• 0001628280-24-051683.txt ( ) — 203KB
• skin-20241212.xsd (EX-101.SCH) — 2KB
• skin-20241212_def.xml (EX-101.DEF) — 15KB
• skin-20241212_lab.xml (EX-101.LAB) — 26KB
• skin-20241212_pre.xml (EX-101.PRE) — 15KB
• skin-20241212_htm.xml (XML) — 3KB

01. Regulation FD Disclosure

Item 7.01. Regulation FD Disclosure. On December 17, 2024, the Company issued a press release announcing the appointment of Mr. Fanning as a director of the Board. A copy of this press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. Exhibit 99.1 contains forward-looking statements. These forward-looking statements are not guarantees of future performance and involve risks, uncertainties, and assumptions that are difficult to predict. Forward-looking statements are based upon assumptions as to future events that may not prove to be accurate. Actual outcomes and results may differ materially from what is expressed in these forward-looking statements. The information set forth under Item 7.01 of this Current Report on Form 8-K (this "Current Report"), including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of such section. The information in Item 7.01 of this Current Report, including Exhibit 99.1, shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any incorporation by reference language in any such filing, except as expressly set forth by specific reference in such a filing. This Current Report will not be deemed an admission as to the materiality of any information in this Current Report that is required to be disclosed solely by Regulation FD.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release, dated December 17 , 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: December 17, 2024 The Beauty Health Company By: /s/ Michael Monahan Name: Michael Monahan Title: Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR